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Professors Vitomir Šunjić and Michael J. Parnham, both 
experienced researchers and teachers, joint in an effort 
to produce a monograph on the role of synthetic organic 
chemistry in the discovery and development of new 
drugs. It is not surprising that these two scientists under-
took this task since both are all their scientific lifes 
involved in tracking drugs that might be used in treating 
diseases. 
The aim of their monograph was to demonstrate 
the use of advanced methods of modern synthetic organ-
ic chemistry in producing compounds with desired bio-
logical properties. This involves the consideration of 
their structural, stereochemical and conformational 
features since they represent the foundation for their 
biological action. I wish also to point out that this mo-
nograph is primarily aimed to researchers in organic 
chemistry and medicinal chemistry. Advanced research 
students in these two areas may find the monograph as a 
very helpful source of methods and techniques in both 
advanced preparative chemistry and medicinal chemi-
stry. The monograph may also be a source of inspiration 
for inorganic medicinal chemists who are preparing 
inorganic compounds with possible medical applica-
tions. Interesting enough the publisher classified this 
monograph as to belong to the field of biomedicine. 
The monograph consists of Preface, 16 chapters 
(each chapter is followed by the list of pertinent refer-
ences), brief chapter summarizing synthetic methods 
and concepts discussed in chapters 2–16 and Index. In 
Preface (v–vii) authors pointed out why they prepared 
this monograph. To my mind this monograph presents 
authors' research philosophy exemplified on a set of 15 
selected target structures to demonstrate the power of 
the organic synthesis which resulted in compounds, 
some of which are already established drugs and other 
being tested in clinical trials. The first chapter entitled 
Organic Synthesis in Drug Discovery and Development 
(pp. 1–12) presents succinctly the leading position of a 
compound in drug discovery - one needs first to have a 
chemical and then can test it. The compound may be 
obtained by preparation or isolated from natural sources. 
A great feature of the following 15 chapters, each 
devoted to a given target structure, is an Abstract at the 
beginning of the chapter. The Abstract consists of three 
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parts: Biological target, Therapeutic profile and Synthetic 
highlights. Thus, the reader can briefly be informed about 
the material presented in the chapter. It is also important 
feature of the monograph that each chapter is complete 
in itself. Below we give the titles of the chapters and 
briefly mention the therapeutic use of considered com-
pounds since this reviewer is mostly interested in their 
use and potential to treat ailments:  
 
Chapter 2. Aliskerin Fumarate (pp. 13–27).  
Used for oral treatment of high pressure. 
 
Chapter 3. (R)-K-13675 (pp. 29–43).  
This is a 2-aryloxy-propionic acide derivative. It is a 
lead candidate as a cholesterol-lowering drug. 
 
Chapter 4. Sitagliptin Phosphate Monohydrate (pp.  
45–54).  
Used in treatment of type 2 diabetes mellitus. 
 
Chapter 5. Biaryl Units in Valsartan and Vancomycin 
(pp. 55–68).  
Valsartan is a leading drug in treating hypertension, 
whilst vancomycin is a broad spectrum antibiotic 
 
Chapter 6. 3-Amino-1,4-Benzodiazepines (pp. 69–82).  
Tested for a variety of diseases such as for use in the 
therapy of Alzheimer’s disease.  
 
Chapter 7. Sertraline (pp. 83–102).  
Used for treatment of depression and anxiety-related 
disorders. 
 
Chapter 8. 1,2-Dihydroquinolines (pp. 103–116).  
Candidates for non-steroidal antagonist at the glucocoti-
coid receptor. 
 
Chapter 9. (‒)-Menthol (pp. 117–124).  
Used as a local anaesthetic and analgesic, to reduce itch-
ing, as a gastric sedative agent and as a decongestant. 
Chapter 10. Fexofenadine Hydrochloride (pp. 125–140). 
Used for treating allergic diseases. 
 
Chapter 11. Montelukast Sodium (pp. 141–154). 
Used in the oral treatment of chronic, in particular noc-
turnal asthma. 
 
Chapter 12. Thiolactone Peptides as Antibacterial Pep-
tidomimetics (pp. 155–168). 
In mimicking quorum-sensing peptides, the thiolactone 
peptides act as antibacterials, naturally regulating the 
growth of the bacteria. 
 
Chapter 13. Efavirenz (pp. 169–178). 
Used to treat patients with HIV-1 infection 
 
Chapter 14. Paclitaxel (pp.170–195). 
Used as an anticancer agent with broad spectrum of 
activity against resistent tumours. 
 
Chapter 15. Neoglycoconjugate (pp. 197–225). 
It has potential for the treatment of inflammation and 
cancer 
 
Chapter 16. Aza-Epothilones (pp. 209–223). 
These compounds are potential anticancer agents 
I read an early version of this monograph and the 
final version before it went to printers. It is impressive 
text, though often succint, but specialists write like 
that. However, it also represents an interesting reading 
for scientists in other areas of chemistry, even outside 
of the realm of chemistry, e.g., scientists in medical 
research institutes, university hospitals, pharmaceutical 
industry, etc. 
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